Format

Send to

Choose Destination
See comment in PubMed Commons below
J Exp Clin Cancer Res. 2012 Feb 23;31:16. doi: 10.1186/1756-9966-31-16.

Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis.

Author information

1
Department of Pharmacy, Shanghai First People's Hospital, School of medicine, Shanghai Jiao Tong University, No,100 Haining Road, Shanghai, 200080, China.

Abstract

BACKGROUND:

Antiangiogenic therapy is one of the most significant advances in anticancer treatment. The benefits of antiangiogenic therapies of late-stage cancers have been investigated but are still too limited.

METHODS:

We used an ovarian cancer model to test the effect of short-term bevacizumab treatment on metastasis as measured by bioluminescence. Western blotting and CD34-PAS dual staining were performed to assess hypoxia-inducible transcription factor-1α (HIF-1α) expression and vasculogenic mimicry(VM) formation. Cell viability was examined by a CCK8 assay.

RESULTS:

Bevacizumab demonstrated antitumor effects in models of ovarian cancer, but also accelerated metastasis together, with marked hypoxia and VM formation in mice receiving short-term therapy. Bevacizumab treatment did not affect SKOV3 cell viability and the amount of VM in three-dimensional culture.

CONCLUSION:

These results suggest that antiangiogenic therapy may potentially influence the progression of metastatic disease, which has been linked to the hypoxic response and VM formation.

PMID:
22357313
PMCID:
PMC3310846
DOI:
10.1186/1756-9966-31-16
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center